\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[authoryear]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{www.ijrps.com}{\color{blue}\underline{\smash{www.ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


\usepackage{longtable}

\makeatletter
\AtBeginDocument{\@ifpackageloaded{rotating}{\PassOptionsToPackage{figuresright}{rotating}}{\usepackage[figuresright]{rotating}}\setlength{\rotFPtop}{0pt plus 1fil}\setlength{\rotFPbot}{0pt plus 1fil}}
\makeatother

\makeatletter
 \AtBeginDocument{%
  \@ifpackagewith{endfloat}{figuresonly}
  {\DeclareDelayedFloatFlavor{sidewaysfigure}{figure}}%true
  {\@ifpackagewith{endfloat}{tablesonly}{\DeclareDelayedFloatFlavor{sidewaystable}{table}\DeclareDelayedFloatFlavor{longtable}{table}\DeclareDelayedFloatFlavor{landscape}{table}}%true
  {\@ifpackageloaded{endfloat}{\DeclareDelayedFloatFlavor{sidewaysfigure}{figure}\DeclareDelayedFloatFlavor{sidewaystable}{table}\DeclareDelayedFloatFlavor{longtable}{table}\DeclareDelayedFloatFlavor{landscape}{table}}{}}%false
  }%false
  }
\makeatother

\begin{document}


\def\RunningAuthor{Akshay Kumar S et al.}
\firstPage{260}
\articleType{Review Article}
\receivedDate{18.07.2019}
\acceptedDate{26.10.2019}
\revisedDate{19.10.2019}
\journalVolume{2020, 11}
\journalIssue{1}
\journalDoi{ijrps.v11i1.1815}
\copyrightYear{2020}
\def\authorCount{4}
\def\affCount{1}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{\textbf{The insights on Oro-dispersible tablet}}
\author{Akshay~Kumar~S,  
            Gowda~D~V\textsuperscript{*},  
            Sharadha~M, 
            Akhila~A~R~\\[5pt]{Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education \& Research, Mysuru - 570015, Karnataka, India}}

\begin{abstract}
 Orodispersible tablets (ODTs) were the conventional product that disintegrates or dissolves into the buccal mucosa in less than 1mins in the absence of water and without chewing. They were first acquainted with the market during the 1980s, and end up one of the quickest developing subdivisions of the oral medication conveyance industry and their items are creating at an extraordinary rate. New orodispersible tablet innovations address numerous pharmaceutical and need of patients, extending from upgraded life-cycle the executives for reasonable medicating for pediatric, aged, and mental patients with trouble in swallowing. These supposedly affect about 35\% of the all-inclusive community and related to various ailments like Parkinsonism, mental incapacity, motion sickness, obviousness, water inaccessibility, and so on. Other individuals possibly will face difficulties by utilizing control release solid oral product comprise the psychologically ill, partially developed patients, and rare patients those are unco-operative, on taking place diminished fluid consumption and are nauseated. To defeat such troubles, orodispersible tablets have been formulated. In this dosage form, the property of ODTs can be reached by the expansion of various additives such are super- the disintegrating agent is the main excipient. This has been motivated by both industry and academia to develop advanced orally dispersible products and advanced methodologies in the market. The ODTs are the most extensively implemented marketable products than others. The main purpose of this review paper is to provide the complete information of ODTs formulation. 
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}ODTs,\newline Super disintegrants,\newline Dysphagia,\newline Parkinsonism.
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Gowda~D~V~\\ Phone:\ +91-9663162455~\\  Email:\ dvgowda@jssuni.edu.in
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{www.ijrps.com}{www.ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
During the last decade, the importance of the improvement of the orally disintegrating tablet has been massively extended as it has a significant influence on the comfortable of a patient. In spite of increasing importance in the conventional release of drug delivery systems, the widely known medications they were administered to be absorbed, disintegrate, and discharge the medicament quickly in the GI Tract and still leftovers the dosage form of superior selection. DTs were core, or coated tablets are administered to disintegrate into the water giving a uniform distribution before administration. Therefore the appropriate selection of the disintegrating agent and its reliability of performance for improvement of such tablet formulations are critically important. The administrations of the medications to the older patients have turned into a major barrier in medication treatment, basically because of the difficulty in swallowing disability. ODT offers  a benefit for people who have been facing trouble in administering. This has been accounted for dysphagia is communal amongst all groups of age and further precise, patients with nausea, vomiting, motion sickness complications \unskip~\citep{635025:14882503}. Enhancing the better taste and flavor of ODTs will increase the appropriateness of bitter medications for numerous groups of the populace.


\begin{table*}[!htbp]
\caption{\boldmath {\textbf{ODTs Classification }} }
\label{tw-a2897802ba1a}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.25520000000000003\linewidth-2\tabcolsep}p{\dimexpr.24479999999999997\linewidth-2\tabcolsep}p{\dimexpr.25\linewidth-2\tabcolsep}p{\dimexpr.25\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor} & 1\ensuremath{^{st}} generation ODTs & 2\ensuremath{^{nd}} generation ODTs & 3\ensuremath{^{rd}} generation ODTs\\
\tblmidrule 
Methodology &
  1. By freeze-drying process \mbox{}\protect\newline  &
  1. wet granulation method \mbox{}\protect\newline 2. Drying the medication and excipients after compressing their wet mass &
  1. Dry granulation technique \mbox{}\protect\newline 2. Drying the mass containing the drug and saccharides were compressed\\
Advantages &
  Rapid disintegration of ODTs &
  Rapid disintegration of ODTs &
  1. Rapid disintegration of ODTs \mbox{}\protect\newline 2. Less friable than the first generation\\
Disadvantages &
  1. Handling was difficult because the tablets were very friable \mbox{}\protect\newline 2. Highly sensitive to moisture \mbox{}\protect\newline 3. No taste-masking compounds applied for bitter-tasting drugs \mbox{}\protect\newline 4. Low density and hardness &
  1. low hardness of tablets \mbox{}\protect\newline 2. High porosity \mbox{}\protect\newline Low density &
  1. High porosity \mbox{}\protect\newline 2. Low density \mbox{}\protect\newline 3. low hardness\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Examples of Coloring agent}} }
\label{tw-3ed0930a33a3}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.4688\linewidth-2\tabcolsep}p{\dimexpr.5312\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Fd \& c approved color & Comman Name\\
\tblmidrule 
Yellow 5 &
  Tartrazine\\
Yellow 6 &
  Sunset yellow\\
Red 3 &
  Erythrosine\\
Red 40 &
  Allura red\\
Blue 1 &
  Brilliant blue\\
Blue 2 &
  Indigotine\\
Green 3 &
  Fast green\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
USFDA outlined ODTs  as "A solid dosage form comprising of API that breakdown rapidly generally within 1 minute once located on the tongue." ODTs disintegration time usually varies from seconds to about a minute.

United States Pharmacopoeia (USP) approves the terminology of these dosage forms as ODTs. In recent times, EP has been made use of the word oro-dispersible tablet, which dissolves immediately and inside 3 minutes in the buccal cavity prior to swallowing. ODTs are also named as oro-dispersible, quick-disintegrating, mouth-dissolving, fast-dissolving, rapid melts, and porous tablets. Presently such tablets in market exit to treat numerous therapeutic disorders such are pre \& post-operative pain, headache, nausea, vomiting, high blood pressure, etc. \unskip~\citep{635025:14882504}.
    
\section{Materials and Methods}
\textbf{Classification of ODTs }

The ODT's are classified, as shown in Table~\ref{tw-a2897802ba1a}.

\textbf{Destination of oro-dispersible }

Oro-Dispersible is recognized from control release sublingual tablets, buccal tablets, and lozenges, which want over a moment to break down in buccal mucosa. In the absence of water, a freeze-dried wafer is quickly disintegrated. To assure the stability for this dosage form physically, this needs single-dose packing. These wafers break down immediately and discharge drug in the buccal mucosa, which disperses in the salivation, and further, it is swallowed, and absorption of the drug takes place in GI-Tract.

An ODT once positioned in the buccal mucosa, which contains therapeutic excipients and breaks down quickly in the absence of water. The medication is discharged, breaks down in the salivation, then swallowed and absorbed in the GI-Tract. A rapidly break down tablet is a solid oral tablet that will swallow in the absence of water, which breakdown inside 60 sec when positioned in the buccal mucosa. The therapeutic excipients are dissolved and absorbed over the buccal membrane and GIT, which move across the systemic circulation. Little quantity of pre-gastric medicament absorption might evade the gastrointestinal system and metabolize by the enzymes and stomach acids \unskip~\citep{635025:14882505}.

\textbf{Salient features of ODTs}


  
  \begin{enumerate}
  \item \relax  Administration of dosage form to patients with difficulties in swallowing is simple.
  \item \relax Accurate in dose as compared to oral-liquids.
  \item \relax In the absence of water, the medication can be administered, helpful for people who are in the journey, and not have instant facilities of drinking water. 
  \item \relax Certain medications were absorbed from the buccal cavity, pharynx, and esophagus by means of salivation move across the digestive system, and then the availability of drugs is expanded.
  \item \relax Absorption develops bioavailability by not experiencing the first-pass metabolism reduce the dose, and then enhanced scientific execution over the decreased undesirable effects.
  \end{enumerate}
  \textbf{Ideal-properties of oro-disintegrating tablets }

The execution of ODTs relies upon the technology, which is utilized during their industrial process. The significant property of these tablets is the capacity to break down quickly and dissolve in salivation, thereby avoiding the requirement for water.

\textbf{It should meet the below conditions}


  
  \begin{enumerate}
  \item \relax It should degenerates and break down within 60 seconds in the absence of water.
  \item \relax It must require enough ability to bear the conditions like the stiffness of the industrial process and post-manufacturing handling. 
  \item \relax Must permit more doses filling.
  \item \relax Show low affectability to environmental conditions like temperature and humidity.
  \item \relax It is more precise dosing.
  \item \relax It should be convenient without friability worry.
  \end{enumerate}
  
\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Limits of} \textbf{ Flow Properties powder}} }
\label{tw-811adc184408}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2089\linewidth-2\tabcolsep}p{\dimexpr.3905\linewidth-2\tabcolsep}p{\dimexpr.4006\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}SL/No. & \ensuremath{\theta } = tan-1 h/r  & Flow type \\
\tblmidrule 
1 &
  {\textless}20  &
  Outstanding \\
 2 &
  20-30  &
  Good \\
 3 &
  30-40  &
  Better \\
4 &
  {\textgreater}40  &
  Poor \\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{Mouthfeel}

It is a major property, and people must get medicine, which senses pleasant and sweetened.

Foaminess is added to help in the breakdown, and mouth-feel can be enhanced by reducing the ``waterlessness'' of a drug. 

\textbf{Friability}

In request to enable ODTs to disintegrate in the buccal cavity, which are comprised of whichever extremely leaky or compacted to tablet by means of applying low compression force and cause the product friable are hard to deal with, frequently need specific peel-off blister packing. To defeat this kind of issue, a few organizations presented progressively strong types of fast dissolving tablets, for example, Wowtab and Dura Solve \unskip~\citep{635025:14882506}.

\textbf{Advantages of orodispersible tablet}\ensuremath{^{}}

1. Quick drug therapy interference.

2. ODTs are considered to be the desired dosage form for Rapid drug delivery.

3. Medication is discharged rapidly from this dosage form and gets break up in the GIT tract without getting into the stomach; improved bioavailability can be accomplished.

4. ODTs are advantageous for administrating to a different category of patients from disabled, explorers, and busy people, who don't generally approach the water. 

5. It creates great mouth feel property, which changes the impression of medication. This factor is valuable while formulating a dose for pediatric patients. 

6. Enhanced patient compliance.

7. Delicate medicine for the acidic condition can be intended as ODTs.

8. No water required.

9. No chewing required.

10. Improved taste. 

11. Improved stability.

12. Appropriate for conventional release studies.

13. Permits more doses filling.

14. Leave the least possible residue.

15. Cost-effective \unskip~\citep{635025:14882507}.

 \textbf{Disadvantages of Orodispersible tablets }

1. These are highly hygroscopic, so care has to be taken while storage. 

2. Dosage form, which is having very high doses, is challenging to formulate into Oro-dispersible. 

3. Due to its porous structure, ODTs are highly fragile sometimes.

4. The safety and proper stabilization for a stable product that needs unit-drug packaging. 

5. After taking ODTs special precautions must be taken, like eating and drinking may become restricted for some time \unskip~\citep{635025:14882508}.


\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Relationship between Carr's index and Flowability}} }
\label{tw-d9ed82dc50ef}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2418\linewidth-2\tabcolsep}p{\dimexpr.3749000000000001\linewidth-2\tabcolsep}p{\dimexpr.3833\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}SL/NO & Carr's index & Flow Property \\
\tblmidrule 
1  &
  5 {\textendash} 15  &
  Outstanding \\
2  &
  12 {\textendash} 16  &
  Good \\
3 &
  18 {\textendash} 21  &
  Better \\
4 &
  23 {\textendash} 35  &
  Poor \\
5 &
  33 {\textendash} 38 &
  Very bad \\
6 &
  {\textgreater} 40 &
  Extremely bad \\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{Need for development of ODTS}

The requirement for Noninvasive route persists is due to patients deprived acceptance and compliance with the current route of administration of drug regimes, the limited commercial scope for pharmaceuticals firms, and its product uses, in account to increase the cost of disease-organization.

\textbf{Patient factors }


  
  \begin{enumerate}
  \item \relax Pediatrics and old aged people are having difficulties in administering or consumption of solid-orals.
  \item \relax Patients who are the concern of choking it is only because of unwilling to in the administration of the solid-oral formulation. 
  \item \relax Terribly old-aged peoples might be not ready to administer a regular dosage of anti-depressant drugs.
  \item \relax Aged lady undertaking radioactivity treatment for a breast tumor is also too nauseating to administer H2-beta-blocker \unskip~\citep{635025:14882509}.
  \end{enumerate}
  \textbf{Efficacy factor}

Improved availability of the drug and quicker release of the drug are severe factors of those dosage-forms. Drug absorbed in the salivation of the buccal cavity, which affects the pre-gastric absorption from various dosage forms. In such cases, the drug was dissolved rapidly.

Oral mucosa, throat, and GI in all these areas absorption of various drugs. Some Pre-Gastric absorption evades 1\ensuremath{^{st}} pass-metabolism and which might an excellent benefit in a medicinal product that endures an excellent interest in the metabolism of an internal organ \unskip~\citep{635025:14882510}.

\textbf{Manufacturing and marketing factors}

Evolving innovates technologies for the drug delivery system and which help in growth for pharma-industries to persist, regardless of their growth size in the market. As the product loses its patent life, which is communal for pharma-manufacturers to improve the medicinal product. A new dose permits an industrialist to improve commercial exclusiveness, distinctive product difference, business postponement, and prolong patent security while providing their patients with a new appropriate dosage form, which results in improved income.


\begin{table*}[!htbp]
\caption{\boldmath {Weight VariationSpecification as per IP} }
\label{tw-9a1deb7febdd}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.55879999999999995\linewidth-2\tabcolsep}p{\dimexpr.44120000000000005\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Average weight & \% variation\\
\tblmidrule 
\ensuremath{\leq }80 mg &
  \ensuremath{\pm}10\\
\ensuremath{\geq } 80 mg to \ensuremath{\leq } 250 mg &
  \ensuremath{\pm}7.5\\
\ensuremath{\geq }250 mg &
  \ensuremath{\pm}5\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{Problems with current solid orals }


  
  \begin{enumerate}
  \item \relax Patients might experience the ill effects of tremors; in this manner, they may feel problems in taking fine particles and fluid medicine. In facing problems in swallowing, mental obstacles and adhering to throat might result in duodenal ulcer.
  \item \relax It will cause difficulty in the improvement of the muscular and sensory system for young adults by facing problems in the incorporation of solid orals.
  \item \relax Fluid medicines are filled in multi-dose bottles: in this way, contented consistency in every dosage portion may not be kept up.
  \end{enumerate}
   \textbf{Challenges in formulating ODTs }

\textbf{Palatability}

 Various medications stay unpleasant; solid-orals sometimes comprise the medicines in a palate taste screened form. The drug delivery system dissolves the drug in the patient's oral mucosa. Then their active therapeutic substance will come across to taste buds, and therefore, taste covering of the drug becomes a critical parameter for comfortable of the patient.

\textbf{Mouthfeel}

The ODTs after disintegration, particles formed must be very small, and it would not have adherence to any residue in the buccal cavity after oral administration with adding of flavoring and cooling agents like menthol will enhance mouth feel. 

\textbf{Mechanical strength}

In request to enable ODTs to disintegrate in the buccal cavity, which are comprised of whichever extremely leaky or compacted to tablet by means of applying low compression force and makes the product friable are hard to deal with, frequently need specific peel-off blister packaging.\ensuremath{^{}}

\textbf{Hygroscopicity}

So many oro-dispersible products were not able to maintain physical reliability under the standard conditions of temperature and humidity due to hygroscopic. Therefore, they need to protect the product from moisture, which involves the specialized product packaging.

\textbf{Quantity of drug}

The utilization of technologies for ODTs is restricted by means of the amount of drug incorporated in a single dose. Lyophilized drug products for which insoluble and soluble drugs dose should be below 400mg and 60mg. Therefore, the amount of drugs is very crucial for the development of oro-dispersible films or wafers. 

\textbf{Aqueous solubility\ensuremath{^{}}}

This parameter has more product development challenges, which are result in the formation of eutectic mixtures. In Further, they will cause the freezing point depression and leads to the development of glassy solid, which might breakdown during drying because of the loss of structure during the sublimation process. By utilizing a matrix-forming substance, such collapses can be prevented \unskip~\citep{635025:14882532}.

\textbf{Excipients required for the formulations of oro-dispersible }

\textbf{The below excipients were required in the development of ODTs}

\textbf{Superdisintegrants}

The pharmacists are required to develop and formulate fast disintegrating formulation by using various super disintegrating agents for the immediate release of the active ingredient. These agents are in effect at lower concentration and which have the higher dispersible capability and are more ineffective at Intra granularly. 

It acts by the swelling mechanism, which leads to pressure release within the radial or outer direction. Further, it will cause a tablet to burst and result in an increase in the volume of granules to cause disintegration.

It is regularly used in tablet and capsule formulations to stimulate penetration of moisture and break down of matrix of formulation in fluids.


\begingroup
\makeatletter\if@twocolumn\@ifundefined{theposttbl}{\gdef\TwoColDocument{true}\onecolumn\onecolumn}{}\fi\makeatother \setlength\LTcapwidth{\textwidth}
\begin{longtable}{p{\dimexpr.05870000000000003\linewidth-2\tabcolsep}p{\dimexpr.21809999999999995\linewidth-2\tabcolsep}p{\dimexpr.20419999999999998\linewidth-2\tabcolsep}p{\dimexpr.2803\linewidth-2\tabcolsep}p{\dimexpr.2387\linewidth-2\tabcolsep}}
\caption{\boldmath {\textbf{Brief details regarding Recent Research on ODTs}} }
\label{tw-f87c6ab569a5}
\def\arraystretch{1.1}\\\endfirsthead \hline \noalign{\vskip3pt} \noalign{\textit{Table \thetable\ continued}} \noalign{\vskip3pt} 
\tbltoprule \rowcolor{kwdboxcolor}S.No & Drug (therapy \mbox{}\protect\newline category) & Method used & Excipients used  & Result\\
\tblmidrule \endhead \hline \noalign{\vskip3pt} \noalign{\textit{\hfill Continued on next page}} \noalign{\vskip3pt} \endfoot \endlastfoot 
\tbltoprule \rowcolor{kwdboxcolor}S.No & Drug (therapy \mbox{}\protect\newline category) & Method used & Excipients used  & Result\\
\tblmidrule 
1 &
  Aceclofenac \mbox{}\protect\newline (Non-Steroidal Anti-Inflammatory Drug) &
  Direct \mbox{}\protect\newline compression &
  MMC, CCS, sodium starch glycolate, &
  Decreased Disintegration time, faster dissolution.\\
2 &
  Nateglinide(anti \mbox{}\protect\newline hyperglycemic \mbox{}\protect\newline agent) &
  Direct \mbox{}\protect\newline compression &
  Pregelatinized starch, \mbox{}\protect\newline sodium starchglycolate, \mbox{}\protect\newline crospovidone. &
  Better patient \mbox{}\protect\newline compliance,\\
3 &
  Celecoxib (NSAID) &
  Direct \mbox{}\protect\newline compression &
  Microcrystalline cellulose, crospovidone, ACDI sol &
  Increased \mbox{}\protect\newline Bioavailability\\
4 &
  Rosu-vastatin \mbox{}\protect\newline (HMG-CoA \mbox{}\protect\newline reductase) &
  Dispersions \mbox{}\protect\newline of solid &
  Mannitol, sodium Starch glycolate, PEG-6000, Pregelatinized starch, Croscarmellose sodium. &
  Improve the rate of \mbox{}\protect\newline dissolution and solubility of the drug.\\
5 &
  Cinnarizine \mbox{}\protect\newline (H1-antagonist receptor) &
  Sublimation &
  sodium saccharine , MMC, Croscarmellose \mbox{}\protect\newline sodium, sodium starch \mbox{}\protect\newline Glycolate, camphor. \mbox{}\protect\newline  &
  Improve the bioavailability and \mbox{}\protect\newline Patient compliance and which will cause the rapid onset of action,\\
6 &
  Promethazine \mbox{}\protect\newline chocolate(anti \mbox{}\protect\newline histamine) &
  Direct \mbox{}\protect\newline compression &
  Microcrystalline \mbox{}\protect\newline cellulose, camphor, \mbox{}\protect\newline crospovidone, \mbox{}\protect\newline mannitol, actress, \mbox{}\protect\newline \ensuremath{\beta } - cyclodextrin. &
  89\% Drug \mbox{}\protect\newline release in 5 \mbox{}\protect\newline mins.\\
7 &
  Domperidone \mbox{}\protect\newline (anti-emetic) \mbox{}\protect\newline and Omeprazole \mbox{}\protect\newline (a proton pump \mbox{}\protect\newline inhibitor) &
  Direct \mbox{}\protect\newline compression &
  Croscarmellose , Ac-Di-Sol, Kollidon CL, Sodium starch \mbox{}\protect\newline glycolate &
  Poor aqueous \mbox{}\protect\newline solubility\\
8 &
  Metformin \mbox{}\protect\newline hydrochloride(oral \mbox{}\protect\newline antidiabetic \mbox{}\protect\newline biguinide agent,) &
  Direct \mbox{}\protect\newline compression &
  MCC, Mannitol, Croscarmellose \mbox{}\protect\newline Sodium, crospovidone, sodium starch glycolate &
  Within 30mins, 98.7\% drug was released.\\
9 &
  Carbamazepine \mbox{}\protect\newline (tricyclic antidepressants) &
  Solid dispersions &
  SLS, PEG-6000, PVP, MCC, Croscarmellose Sodium , Aspartame &
  Improved \mbox{}\protect\newline bioavailability, \mbox{}\protect\newline better patient compliance.\\
10 &
  Lisinopril (ACE \mbox{}\protect\newline inhibitors) &
  Direct \mbox{}\protect\newline compression &
  Croscarmellose Sodium, \mbox{}\protect\newline Crospovidone, Sodium starch glycolate, Mannitol &
  Within 30 mins, the Drug was released is 99.99\% and which will be enhanced dispersible time\\
11 &
  Oxcarbazepine \mbox{}\protect\newline (NSAID) &
  Wet granulation &
  Avicel pH 102, \mbox{}\protect\newline Aerosil &
  Enhanced dissolution\\
12 &
  Valsartan (antihypertensive) &
  Direct \mbox{}\protect\newline compression &
  AC-DI-SOL, Sodium saccharine, Crospovidone, Sodium starch glycolate, MCC &
  Greater bio availability,\\
\tblbottomrule 
\end{longtable}
\endgroup
\makeatletter\@ifundefined{TwoColDocument}{}{\twocolumn}\makeatother 

\begin{table*}[!htbp]
\caption{\boldmath {\textbf{Brief details regarding Recent Research on ODTs}} \textbf{(\textit{Continued From Table 6})} \mbox{}\protect\newline }
\label{tw-d542772c996c}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.0712\linewidth-2\tabcolsep}p{\dimexpr.22490000000000002\linewidth-2\tabcolsep}p{\dimexpr.1736\linewidth-2\tabcolsep}p{\dimexpr.286\linewidth-2\tabcolsep}p{\dimexpr.2443\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}S. \mbox{}\protect\newline No & Drug (therapy \mbox{}\protect\newline category) & Method used & Excipients used & Result\\
\tblmidrule 
13 &
  Etoricoxib \mbox{}\protect\newline (NSAID) &
  Direct \mbox{}\protect\newline compressio &
  Urea, Croscarmellose, \mbox{}\protect\newline Avicel &
  rapid dissolution , enhance patient compliance, quick DT\\
14 &
  Granisetron HCL &
  Direct \mbox{}\protect\newline compression &
  Croscarmellose\c{} Crospovidone &
  Enhanced \mbox{}\protect\newline Dissolution rate\\
15 &
  Ramipril \mbox{}\protect\newline (Antihypertensive &
  Wet \mbox{}\protect\newline granulation &
  Sodium bicarbonate, Polyvinyl \mbox{}\protect\newline pyrrolidone, Citric acid, Mannitol &
  Rapid \mbox{}\protect\newline disintegration \mbox{}\protect\newline and \mbox{}\protect\newline dissolution\\
16 &
  Rizatriptan benzoate \mbox{}\protect\newline (Serotonin 5-HT \mbox{}\protect\newline receptor agonist) &
  Mass \mbox{}\protect\newline extrusion &
  Crospovidone , Eudragit EPO, Croscarmellose sodium, Sodium starch glycolate, Pearlitol SD200 &
  Complete taste \mbox{}\protect\newline masking ,rapid \mbox{}\protect\newline disintegration \mbox{}\protect\newline and dissolution\\
17 &
  Ebastine \mbox{}\protect\newline (2\ensuremath{^{nd}}generation \mbox{}\protect\newline non{\textendash}sedating H1 -receptor antagonist) &
  Sublimation &
  PVP, Camphor, Mannitol, Sodium saccharine, Ammonium bicarbonate, Microcrystalline  &
  Improved dissolution, faster \mbox{}\protect\newline disintegration \mbox{}\protect\newline ({\textless}1 min)\\
18 &
  Clonazepam \mbox{}\protect\newline (Antiepileptic) &
  Direct \mbox{}\protect\newline compression &
  Crospovidone, Croscarmellose, Directly \mbox{}\protect\newline Compressible Mannitol, \mbox{}\protect\newline Microcrystalline cellulose &
  Enhanced patient compliance\\
19 &
  Isoxsuprine \mbox{}\protect\newline hydrochloride \mbox{}\protect\newline (Vasodilator) &
  Direct \mbox{}\protect\newline compression &
  Microcrystalline \mbox{}\protect\newline cellulose, Crospovidone, \ensuremath{\beta }-cyclodextrin, Ac-di-sol, Sodium starch \mbox{}\protect\newline glycolate, Mannitol &
  High release \mbox{}\protect\newline rate\\
20 &
  Levocetrizine \mbox{}\protect\newline hydrochloride \mbox{}\protect\newline ( Non-sedative \mbox{}\protect\newline anti-histaminic) \mbox{}\protect\newline  &
  Direct \mbox{}\protect\newline compression &
  Croscarmellose,Primojel, \mbox{}\protect\newline Crospovidone,MCC \mbox{}\protect\newline  &
  Improved bio \mbox{}\protect\newline availability, rapid onset of \mbox{}\protect\newline action\\
21 &
  Meclizine \mbox{}\protect\newline hydrochloride \mbox{}\protect\newline (Antiemetic) &
  Direct \mbox{}\protect\newline compression &
  Crospovidone XL 10, Avicel pH 102, Pearlitol SD 200 &
  Rapid disintegrate-on, quick onset of \mbox{}\protect\newline action\\
22 &
  Montelukast \mbox{}\protect\newline Sodium \mbox{}\protect\newline (Antineoplastic &
  Direct \mbox{}\protect\newline compression &
  Crospovidone, Sodium starch glycolate, Mannitol, Microcrystalline cellulose &
  Enhanced \mbox{}\protect\newline \\
23 &
  Salbutamol \mbox{}\protect\newline Sulphate (\ensuremath{\beta }2 \mbox{}\protect\newline receptor \mbox{}\protect\newline agonist &
  Direct \mbox{}\protect\newline compression &
  Microcrystalline Mannitol-D, cellulose, Propyl cellulose, \mbox{}\protect\newline Primogel, L-hydroxy &
  Rapid dissolution and \mbox{}\protect\newline Rapid onset of action \mbox{}\protect\newline \\
24 &
  Telmisartan \mbox{}\protect\newline (Antihypertensive) &
  Direct \mbox{}\protect\newline compression &
  Skimmed milk \mbox{}\protect\newline powder, Poloxamer-188, \mbox{}\protect\newline Crospovidone &
  Better solubility, \mbox{}\protect\newline Rapid disintegration and high dissolution rate\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{List of Super-disintegrants}


  
  \begin{enumerate}
  \item \relax Microcrystalline cellulose
  \item \relax Sodium starch glycolate
  \item \relax Crospovidone
  \item \relax Cross Carmellose Sodium
  \item \relax Pregelatinized starch
  \item \relax Calcium CMC
  \item \relax Modified corn starch
  \end{enumerate}
  \textbf{Mechanism of Super-disintegrants}

The breakdown of the tablets into the small particles by various following mechanisms:\textbf{\space }

\textbf{Capillary Action}

Breakdown of the drug due to capillarity is the first stage. The tablet is placed into the suitable aqueous media than the media enters the tablet and which is substituted by air adsorbed on constituents. Further, this will deteriorates the inter-molecular bond and disperse the tablet into fine particles.

\textbf{Swelling}

In general, this mechanism was most widely accepted for the dispersion of tablets by swelling with great porosity and which result in slow disintegration due to lack of sufficient swelling force. The particles of the tablet will swell and breaks up the matrix, swelling sets up, and localized stress spreads throughout the matrix.

\textbf{Due to Heat of Wetting (Air Expansion)}

Due to the heat discharging properties, disintegrants get wetted and local stress released because of air expansion, which results in the breakdown of the tablet into particles. 

\textbf{By Release of Gases}

The chemist incorporates effervescent powder in a tablet blend prior to compression. Due to the wetting of the tablet, CO\ensuremath{_{2}} is released within a tablet because of the reaction between HCO\ensuremath{_{3}}+ CaCo\ensuremath{_{3}} with citric acid. Therefore, the disintegration of the tablet takes place due to the release of pressure within the tablet. 

\textbf{Enzymatic Reaction}

The enzymatic reaction occurs due to the enzymes available within the body act as disintegrants, and then these spoil the binding property of binder, which disintegrates.

\textbf{Particle Repulsive Forces}

In this mechanism, the non-swellable particle is used in the formulations which disintegrate tablet due to repulsive electric force within the particles and for this water is needed. 

\textbf{Due to Deformation}

During compression of the tablet, the disintegrating agent particles become partial-misshapen particles that enter into the main structure after coming contact to aqueous media. These results in misshapen particle size increased and caused the breakdown of tablets \unskip~\citep{635025:14882511}.

\textbf{Bulking agents}

These bulking agents act as filler, dilatant, and cost-effective, which is significant in the formulations of ODTs. It will develop the textural property, which improves the disintegration within the buccal cavity. The advised bulking materials for these ODTs would be more sweetening agents.

E.g. CaCo\ensuremath{_{3}}, MgCaCo\ensuremath{_{3}}, Mannitol, CaSO\ensuremath{_{4}}etc.

\textbf{Emulsifying Agents}

This agent helps in fast disintegration and release of drug from the formulation by swallowing or in the absence of water or by devoid of chewing. It will be also helpful in improving the bioavailability and stabilize the unmixable blend.

Eg. PEG-Ester, Alkyl sulfates, Sucrose ester etc.

\textbf{Sweetening agent } \textbf{\space }

These agents act as filler or diluent or bulking agents, which show more water solubility, sugariness, and impart palate\textbf{\space }screening features.

Eg- NATURAL: Dextrose, Sucrose, Mannitol, Lactose.

 ARTIFICIAL: Cyclamate, Aspartame, saccharin. 

\textbf{Flavoring agent}

These agents will improve the taste, patient's comfort, and acceptance.

E.g.- Strawberry, Vanilla, Fruit essence, Peppermint oil, menthol etc.

\textbf{ Surface Active agents}

These agents will decrease the surface tension and improve the solubility.\textbf{\space }

E.g., SLS, Polyoxyethylene sorbitol fatty acid esters, etc.

\textbf{Binders} \textbf{\space }

These agents will provide cohesive strength to powdered materials, which leads to forming granules. Therefore, these agents help in maintaining the stability and integrity of the tablet. 

E.g., HPMC, PVP, PVA.

\textbf{Colorings Agents} \textbf{\space }

These agents help in improving the organoleptic and appearance of the drug product. The examples of coloring agents are shown in Table~\ref{tw-3ed0930a33a3}.

\textbf{Lubricants} \textbf{\space }

These agents are used to decrease the friction and prevent adhesion of tablet between the die walls. It also helps in the easy ejection of pills from the cavity and in the transport of drugs from the oral cavity to the GIT. 

E.g., Talc, PEG 400, Paraffin, Mg-stearate, Zn-stearate, etc

\textbf{Formulation methods of oro-dispersible }

The common methodologies to manufacturing Oro-Dispersible are described as below

\textbf{Spray drying }

This method is widely used in pharma-industries and in biochemical procedures, which helps in the rapid ejection of the liquid and gives a porous or fine powder. The tablets were formulated by compression of dried spray powder, and disintegrating agents like sodium starch glycolate or Crospovidone or Croscarmellose sodium were used to enhance the disintegration time and dissolution profile. Therefore, it shows the disintegration time of 20 seconds \unskip~\citep{635025:14882512}. 

\textbf{Sublimation }

In the conservative method, compression of volatile substance into tablets and these substances removed by sublimation process at the temperature range of 40\ensuremath{^{0}}C- 60\ensuremath{^{0}}C. Further, this results in a porous structure and gives 25 seconds of disintegration time \unskip~\citep{635025:14882513}.

\textbf{Freeze drying}

In this process, solvents were removed from the frozen product comprising structure developing substances at very low in temperature to remove adverse thermal reaction and which will cause a change in the stability of the drug. The products prepared by this technique were generally low in weight, which has high porousness, and that results in fast dissolution\unskip~\citep{635025:14882514}. 

\textbf{Molding }

In this process, the blend mixed with solvent such are water and ethanol, and then this mixture was passed through a fine screen and molded into tablets under high pressure, which lead to improving the dissolution profile. Therefore, this method is also called has compression molding \unskip~\citep{635025:14882515}. 

\textbf{Mass extrusion}

In this method, the blended mixture was softened with a mix of solvent water-soluble PEG and methanol. This softened blend mixture was filled in the syringe and ejected to form a cylindrical product. This product is then made into small pieces by using a heated blade, which results in the formation of tablets \unskip~\citep{635025:14882516}. 

\textbf{Direct compression }

In this process, the powder blend is prepared by dry or wet granulation method, which is directly compressed into a tablet. These prepared tablets were more friable, disintegrate rapidly, and the cost is less compared to the conventional dosage form.

\textbf{Melt granulation}

In this technique, granules were formed in molten form by adding waxy substances with M.P of 33\ensuremath{^{0}}C to 36\ensuremath{^{0}}C and HLB value of 9. These substances will improve the tablet r{\'e}sistance and which will help in the disintegration of tablets after melting in the oral cavity \unskip~\citep{635025:14882517}.

\textbf{Phase transition process}

In this process, tablets were formulated by compression of blend mixture comprising of sugar alcohols with high and low M.P and which will cause phase transition of sugar alcohols. Therefore, increased bonding between the particle and surface area of the tablet by lowering M.P of sugar alcohol.

\textbf{Nanonization }

In this technique size of the particle was decreased to Nanosize by wet-milling technology, and then these Nano drug particles were stabilized by surface adsorption. Further, these stabilized particles were incorporated into a metered-dose transdermal spray. Therefore, this methodology helpful in the fast dissolution of Nanoparticle for poorly water-soluble drugs and which leads to improvement in absorption, bioavailability, dose reduced, and cost-effective \unskip~\citep{635025:14882518}. 

\textbf{Effervescent Method}

In this method, oro-dispersible were developed by reacting Na\ensuremath{_{2}}HCo\ensuremath{_{3\ }} and citric acid with super disintegrating agents. Further, this mixture blend was heated at 80\ensuremath{^{0}}C and compressed into the tablets.
    
\section{\textbf{\space }Results and Discussion}
\textbf{ODTS patented technologies}

All methodology has various kind of mechanism, and these vary as follows below listed Strength of Finished product Mechanically


  
  \begin{enumerate}
  \item \relax Stability of drug product and drug
  \item \relax Mouthfeel
  \item \relax palatability
  \item \relax The dissolution rate of the drug product in the buccal cavity.
  \item \relax The ability to swallow.
  \end{enumerate}
  \textbf{The listed below are Patented Technologies}

\textbf{Zydis Technology}

Zydis system is an isolated freeze-dried pill wherein the drug is dissolved with the quick-dissolving material. When zydis formulations are situated into the mouth, the freeze-dried constitution disintegrates instantaneous and does now not require water for swallowing. To provide force during dealing with, polymers reminiscent of gelatin, dextran, or alginates are added. To obtain Crystallinity, good appearance, and hardness, saccharides are delivered. Water is used within the manufacturing approach to be a certain production of porous items to gain rapid disintegration. Exceptional gums are utilized to preclude sedimentation of dispersed drug particles in the industrial procedure. Glycine is delivered to restrict the shrinkage of zydis items during the freeze-drying process \unskip~\citep{635025:14882519}. 

\textbf{Durasolv Technology}

CIMA LABS patented this technology, and in this unit are comprised of drugs, lubricants, and bulking agents. Further, this unit is prepared by tablets compression machine and which had better rigidity. These prepared units are packed into blister packaging. This technology is good for those products which required less quantity of API \unskip~\citep{635025:14882520}.

\textbf{Orasolv Technology}

This technology is also developed and patented by CIMA LABS. This technology helps to mask the taste of drugs and which contains foam-forming disintegrating agents. Further, this powder blend compressed to from tablets at low compression forces for improving the disintegration time \unskip~\citep{635025:14882521} .

\textbf{Wow tab Technology}

This technology is developed without the use of water, so it is called Wow and which is patented by Yamanouchi pharmaceuticals. In this method, low and high stability saccharides were combined with API and which result in active, quickly dispersible tablets.

\textbf{Flash Dose Technology }

This technology comprises of the matrix, which is in self-binding shear form, and it is known as "floss," and these shear matrices were prepared by a process called flash heating. 

\textbf{Flash tab Technology }

In this technology, API is made into the microcrystals. Then micro granules are formed due to various techniques such are micro-encapsulation, coacervation, etc. further; these granules were compressed to form tablets.

\textbf{Oraquick Technology}

This technology is also known has microsphere or micro mask technology, which is patented by KV Pharmaceutical. This mainly enhances the taste and mouthfeel, and it doesn't use any kind of solvents for masking the taste. Then this results in the fast production of oro-quick tablets, which is suitable for heat-sensitive drugs.

\textbf{Quick {\textendash}Dis } \textbf{technology}

In this technology, a quick-disintegration film was prepared in which the drug was loaded and placed on the surface of the tongue. This film was evaluated for disintegration time; the film with a thickness of 2 mm starts to break down when it comes in contact with water within 5 to 10 sec. Then, these dosage forms release its 50\% of API below 30 sec and 95\% within 60sec. This technology was developed and patented by Lavi pharma laboratories.

\textbf{Nanocrystal } \textbf{technology}

In this technology, the surface area of the particle was increased by reducing the size of particles, which will improve the dissolution. This can be achieved by utilizing the right Nanocrystal technology in which the particle size of Nano-crystal was less than 1000nm diameter. This size was achieved by blending the drug particles using the best-wet milling method \unskip~\citep{635025:14882522}. 

\textbf{Melt Ease\ensuremath{^{tm}} technology}

This is advanced technology in which tablets with the average size of 400 will disintegrate within 5 sec, and it was the best technology for improving the patient compliance and market by supplying the nutritional product at low cost for the elderly and children.

\textbf{Dispersible tablet technology}

In this technology, tablets were prepared by using a various super disintegrating agents such are sodium starch glycolate, Crospovidone, etc.; these agents will improve the dissolution profile and faster the disintegration of the drug particle by swelling and wetting mechanism of the drug product.

\textbf{AdvaTab technology}

In this technology, the lubricant is applied on the tablet surface by spraying during manufacturing, and it can be prepared by using less than 10-30 times hydrophobic lubricant and 30-40\% harder than a conventional oral tablet. This type of tablet will not inhibit the entry of liquid when it contacts with salivation \unskip~\citep{635025:14882523}.

\textbf{Pharmaburst technology}

In this technology self-coprocessed, excipients were used to develop the oro-dispersible tablets. The API used in this technology is up to 700 mg and pharmaburst concentration of 50-80\%, which will dissolve the drug product within 30-40 sec. Later during manufacture, dry blend of the drug is used and which are compressed into tablets \unskip~\citep{635025:14882524}. 

\textbf{Frosta technology}

In this technology, plastic granules were prepared at the low force of compression and which will result in more porosity with the formation of hard tablets. These granules contain water penetration enhancers, plastic material, and binder. Later, plastic granules were formed, and these granules were compressed into a tablet \unskip~\citep{635025:14882525}.

\textbf{Lyon (Pharmalyoc)}

In this technology, oil in water emulsion was poured directly into the blister cavities, and then the freeze-drying process takes place. During this process, added bulking agents to increase the thickness and avoid Non-homogeneity \unskip~\citep{635025:14882526}. 

\textbf{Evaluation of orodispersible tablets}

\textbf{Preformulation Studies }

\textbf{Angle of Repose}

The powder blend was administration into the funnel, which flows freely on to the surface, and then height and radius of powder cone were measured and calculated for an angle of repose. 
\begin{eqnarray*}\tan\;\theta\;=\frac hr \end{eqnarray*}
Therefore \ensuremath{\theta } = tan-1 h/r

Where: \ensuremath{\theta } = angle of repose,

 h = cone height 

 r = cone base Radius 

The limits for the flow property of powder are shown in Table~\ref{tw-811adc184408}.

\textbf{Bulk Density}

It is defined as the weight of the sample divided by the untapped volume and is conveyed as gm. / cm\ensuremath{^{3}}. 
\begin{eqnarray*}BD\;=\frac W{Bv} \end{eqnarray*}
Where,

BD =Bulk Density

W = Sample weight 

Bv = untapped or bulk volume 

\textbf{Tapped Density}

It is the ratio of the weight of the powder to the tapped volume of the powder. Volume was measured by tapping the powder for 100 times, and the tapped volume was noted. It is expressed in g/ml. 
\begin{eqnarray*}TD\;=\;\frac W{TV} \end{eqnarray*}
 Where, W~is the weight of powder

 The TV is the tapped volume of the powder.

\textbf{Void Volume}

The volume of the space is called as the void volume "v."
\begin{eqnarray*}V=BV-TV \end{eqnarray*}
Where, BV = Bulk volume (volume before tapping)

 TV = True volume (volume after tapping)

\textbf{Carr's index (or) \% compressibility\textit{}}

It indicates the flow properties of the powder. It is expressed in \%.
\begin{eqnarray*}C.I\;=\;\frac{TD\;-BD\;\times100\;\;\;\;\%}{\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;TD} \end{eqnarray*}
Where, TD is tapped density 

 BD is bulk density 

The relationship between Carr's index and flowability is shown in Table~\ref{tw-d9ed82dc50ef}.

\textbf{Hausner's ratio}

A similarity index to show the flow properties of the powder can be explained. 
\begin{eqnarray*}HR\;=\frac{\;TD}{\;BD} \end{eqnarray*}
Where, TD is tapped density.

 BD is bulk density.

\textbf{Post-Compression studies}

\textbf{Tablet thickness}

Thickness is recorded by using ``Vernier Calipers," and which is estimated by taking ten tablets for measurement of thickness.

\textbf{Weight variation}

From the prepared batch, twenty tablets were taken randomly for weighing to check for variation of weight. The limits for weight variation as per IP are shown in Table~\ref{tw-9a1deb7febdd}

\textbf{Friability}

This test was done in the Electro lab Friabilator apparatus and where we take the weight of 10 whole tablets, note down the weight of tablets and perform the friability using Friabilator and report the weight of the tablet after 100 revolutions at 25 RPM \unskip~\citep{635025:14882527}.
\begin{eqnarray*}\%\;Friability\;=\;1-(\frac{Final\;weight\;}{Initial\;weight})\times100 \end{eqnarray*}
\textbf{Hardness\textit{\space }(Crushing strength )}

\textit{\textbf{\space }}The hardness of the tablet is checked with hardness testers by keeping a tablet between the tester, and then a force is applied to break the tablet. The limit for the hardness of uncoated tablet was 3-5 kg/cm\ensuremath{^{2}}\unskip~\citep{635025:14882528}.

\textit{\textbf{\space }} \textbf{Water absorption ratio}

A tablet is placed on the paper, which is two times folded in a small Petri dish comprising water of 6 ml and which is checked for the time needed for complete wetting. Later, wetted tablets are reweighed and calculate the water absorption proportion by given below formula. 
\begin{eqnarray*}R=100\times\frac{W1-W2}{W2} \end{eqnarray*}
Where,

 W1: Tablet weight before absorption of water 

 W2: Tablet weight after absorption of water

\textbf{Uniformity of dispersion}

Place two tablets in 100ml of water and stir gently until completely dispersed. A smooth dispersion is obtained, which passes through a sieve with a nominal mesh aperture (sieve no. 22).

\textbf{Disintegration time\textit{}}

This test was carryout by placing six tablets into the basket each one and maintain at 37\ensuremath{^{0}}C. 

According to the E.P, the quick disintegrating or Orodispersible tablets ought to disintegrate within 3 minutes while not leaving any residue on the screen. However, The basket is thus positioned within the liquid that it contains only 6 ml of the liquid. The assembly is supported with a heater to take care of temperature at 37\ensuremath{^\circ}C and a magnetic stirrer. DT is noted at 25 pm. One of the modest approaches is to take 6ml of simulated saliva in a measuring cylinder and insert the tablet in it. The liquid is neither shaken nor stirred, and DT is noted \unskip~\citep{635025:14882529}.

\textbf{In vivo disintegration time}

A panel of healthy human volunteers is used to perform this test. The time taken by volunteers to disintegrate by retaining the tablet in the mouth is noted.

\textbf{Taste/ Mouth sensation}

The product received by the patients should feel pleasant. This test is carried out by taking one tablet from each batch for the taste by retaining the tablet on the tongue. 

To analyze the mouth sensation, panels of 5 healthy human volunteers are utilized.

Sample equivalent to 40 mg is placed in the mouth for 10 seconds, and the taste is recorded instantly for 10 secs, 1, 2, 4, and 6 minutes. 

Volunteer's opinion scores are given i.e. 0 = good, 1 = tasteless, 2 = slightly bitter, 3 = bitter, 4 = awful.

\textbf{Dissolution test}

The dissolution test for oro-disintegrating tablets is the same as that of standard tablets. The USP 2 (paddle) at a 50 RPM paddle speed is used to perform this test.

The USP 1 (basket) apparatus is less often used due to the specific physical properties of tablets. \unskip~\citep{635025:14882530}.

\textbf{Clinical studies }

To do clinical studies for oro-dispersible tablets. \textit{In vivo } studies are done to study the behavior of drugs within the oral, esophageal tract, their pharmacokinetics, adequacy, and efficiency. By using gamma-scintigraphy were investigating the residence time within the mouth and stomach through the esophageal tract. The transit time of esophageal and stomach evacuating was compared with the standard tablets and capsules. The fast disintegration tablets were examined and shown improves in the pharmacokinetics properties with standard solid orals \unskip~\citep{635025:14882531,635025:14882528}. 

\textbf{Counseling points for ODTs \ensuremath{^{}}}

The registered pharmacist is advancing in the various technologies and guiding their patients on how to administer the drug dose for their first time. Most of the patients were not known of how to take the orodispersible tablet and which dissolves within the oral cavity make the patient in shock and shows the rapid onset of action. Patents clear their doughts with the pharmacist to avoid misunderstanding or confusion. These formulations were rapid dissolves in the absence of water and used the saliva for a breakdown of the drug. If the volume of saliva is low, then it will slow down the disintegration and decreases the bioavailability of the drug product. 

This dosage form can be easily utilized by children who don't have teeth and patients who are feeling difficulties in chewing. Pharmacists should clearly state the difference between effervescent tablets and dispersible tablets \unskip~\citep{635025:14882509}.

\textbf{Recent research on ODTs}

Various studies have been reported the formulation and evaluation of ODTs of various drugs for different purposes are shown in Table~\ref{tw-f87c6ab569a5} .
    
\section{Conclusions}
The overview of ODT formulation has resolved a number of the issues encountered in the administration of medication to the pediatric and aged patient, which constitutes a large proportion of the world's population. Nowadays, ODTs are available in the market and have OTC products to treat flu symptoms, cold and allergies. These ODTs were formulated as full porous in the structure of the tablet for the rapid dissolution of the tablet matrix with a pleasant taste and with appropriate mechanical strength. Therefore for the rapid disintegration of tablets, super disintegrating agents were used in different concentrations depending on the drugs. The research work is still going on, and more number of manufacturers are formulating fast-dissolving tablets. More number of ODTs products was marketed and which are expressed by utilizing advanced innovative technologies. Therefore, ODTS was formulating for more number of drugs and for various treatments of disease in the future.
    
\section{  Acknowledgement}
The authors express their gratitude to the JSS Academy of Higher Education and Research and JSS College of Pharmacy, Mysuru, for providing necessary support in due course of the work.


    

\bibliographystyle{pharmascope_apa-custom}

\bibliography{\jobname}
\end{document}
